unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
Bloodborne Pathogens · Procurement & Buyer's Guide · Regulatory & Compliance · Application Insights
Viral hepatitis elimination: a procurement checklist for viral-load platforms
Key takeaways
Hepatitis viral-load procurement is programme infrastructure: verify the full quantitative range, standardise reporting conventions across sites, secure written allocation at programme volume, and cite regulatory listing numbers in the contract — then budget per reportable result, not per kit.
- Verify the quantitative range across naive and on-treatment populations, especially the lower limit.
- Standardise units, qualification vocabulary, and undetectable conventions across all sites.
- Secure written consumable allocation with volume bands before treatment scale-up.
- Budget cost per reportable result — including controls, rejects, service, and staffing.
Target audienceProgram Lead, Procurement, Lab Director
Review and references
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-06
2026-10-06
professional use
FAQ
Common questions
Why is the lower limit of quantitation so important for elimination programmes?
Because treatment-response decisions run on suppressed values. A high quantitation floor forces "detected, not quantifiable" results that clinicians cannot trend confidently across visits.
Which regulatory listing should the contract cite?
The listing number for the exact assay configuration in each market — FDA clearance, CE-IVDR marking, or WHO prequalification/EUL as applicable. Brochure claims are not auditable.
How should we compare platform costs?
On cost per reportable result: controls and calibrators, your actual rejection rate, service contracts, and the staffing model the workflow implies. Kit price alone systematically misleads.
What is the most common supply failure in viral-load programmes?
Consumable stock-outs during treatment scale-up waves, because allocation policies were never written into the contract with volume bands and lead times.